02132oam 2200541 450 991070818640332120151005134644.0(CKB)3460000000108867(OCoLC)798496440(OCoLC)651946174(OCoLC)654126262(OCoLC)798566624(EXLCZ)99346000000010886720120708d1998 ua 0engurbn||||a||||txtrdacontentcrdamediacrrdacarrierFDA oversight blood safety and the implications of pool sizes in the manufacture of plasma derivatives : hearing before the Subcommittee on Human Resources of the Committee on Government Reform and Oversight, House of Representatives, One Hundred Fifth Congress, first session, July 31, 1997Washington :U.S. Government Printing Office,1998.1 online resource (iii, 427 pages) illustrationsTitle from title screen (viewed on Oct. 5, 2015)."Serial no. 105-70."Includes bibliographical references.FDA oversight Plasma productsUnited StatesSafety measuresBlood plasmaSafety measuresBloodCollection and preservationUnited StatesSafety measuresBloodCollection and preservationSafety measuresfastBlood plasmaSafety measuresfastPlasma productsSafety measuresfastUnited StatesfastLegislative hearings.lcgftPlasma productsSafety measures.Blood plasmaSafety measures.BloodCollection and preservationSafety measures.BloodCollection and preservationSafety measures.Blood plasmaSafety measures.Plasma productsSafety measures.OCLCEOCLCEOCLCOOCLCQOCLCFOCLCQGPOBOOK9910708186403321FDA oversight3525593UNINA